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Abstract
Background: The role of TNFα in cancer is complex with both pro-tumourigenic and anti-tumourigenic roles 
proposed. We hypothesised that anatomical microlocalisation is critical for its function.
Methods: This study used immunohistochemistry to investigate the expression of TNFα in the tumour islets and 
stroma with respect to survival in 133 patients with surgically resected NSCLC.
Results: TNFα expression was increased in the tumour islets of patients with above median survival (AMS) compared 
to those with below median survival (BMS)(p = 0.006), but similar in the stroma of both groups. Increasing tumour islet 
TNFα density was a favorable independent prognostic indicator (p = 0.048) while stromal TNFα density was an 
independent predictor of reduced survival (p = 0.007). Patients with high TNFα expression (upper tertile) had a 
significantly higher 5-year survival compared to patients in the lower tertile (43% versus 22%, p = 0.01). In patients with 
AMS, 100% of TNFα+ cells were macrophages and mast cells, compared to only 28% in the islets and 50% in the stroma 
of BMS patients (p < 0.001).
Conclusions: The expression of TNFα in the tumour islets of patients with NSCLC is associated with improved survival 
suggesting a role in the host anti-tumour immunological response. The expression of TNFα by macrophages and mast 
cells is critical for this relationship.
Background
Non-small cell lung cancer (NSCLC) is the world's lead-
ing cause of cancer related death. At present, the majority
of patients present with advanced stages of disease which
are not amenable to curative treatment. Even with the
optimal presentation of stage Ia disease, the 5-year sur-
vival is just 67% [1] assuming fitness for surgical resec-
tion. Currently chemotherapy does not offer cure for
patients with NSCLC. Thus, it is vital that new biomark-
ers of disease and novel therapies are developed. It is now
recognised that inflammatory and immune responses
play a key role in cancer development and prevention
[2,3] and it hoped that manipulation of these may yield
novel therapies in the future.
Tumour necrosis factor-alpha (TNFα) is a key and
proximal component of many inflammatory pathways. It
plays a key role in host defence to a variety of pathogens
[4,5], but is also implicated in the promotion of many
inflammatory diseases [6,7], including rheumatoid arthri-
tis and inflammatory bowel disease.
The tumour biology of TNFα however is complicated,
with evidence of both pro-tumourigenic and anti-
tumourigenic activity in animal models [8,9]. Perhaps the
best evidence that the predominant role played by TNFα
is anti-tumourigenic arises from studies of anti-TNFα
strategies for the treatment of inflammatory disease in
man. These show a significant increase in the rate of neo-
plastic disease in patients receiving active treatment, and
no evidence of protection against cancer development
[10-16]. The complete resolution of NSCLC in a patient
following withdrawal of anti-TNFα therapy is also
described [17]. In contrast, the administration of anti-
TNFα has had no significant effect on the progression of
several advanced cancers [18-20]. Furthermore, recombi- * Correspondence: cohri@doctors.org.uk
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nant TNFα is a useful and licensed adjunctive treatment
for sarcoma and melanoma [21,22].
There is therefore debate as to whether or not TNFα
plays a role in NSCLC tumour cytotoxicity or conversely,
tumour progression. Two small studies investigated pre-
viously the mRNA or protein expression of TNFα in
NSCLC, and suggested overall that TNFα expression was
either mildly beneficial but not an independent factor
[23] or neutral [24], respectively. However, the anatomi-
cal localisation of the TNFα expressed was not taken into
account. We have shown previously that the site of
inflammatory cell infiltration in NSCLC is critical in
terms of prognosis. Patients with high expression of mac-
rophages in the tumour islets have extended survival
independently of tumour stage, and these macrophages
demonstrate high expression of TNFα and other cyto-
t o x i c  m a r k e r s,  s u g g e s t i n g  t h ey  a r e  o f  a n  a n t i -t u m o u ri -
genic cytotoxic M1 macrophage phenotype [25,26].
This previous work investigating TNFα expression in
macrophages was aimed primarily at determining the
phenotype of these cells rather than the prognostic signif-
icance of TNFα expression. Due to the nature of the
work, relatively small numbers of patients were studied.
The aim of this study was therefore to assess the prognos-
tic significance of TNFα expression, irrespective of cell
type in NSCLC, paying particular attention to its anatom-
ical microlocalisation, in surgically resected NSCLC in
our complete cohort of patients described previously
[26].
Methods
Study Population
The study was approved by the Leicestershire Research
Ethics Committee. The tissue specimens evaluated were
from patients with NSCLC who had undergone resection
with curative intent at the University Hospitals of Leices-
ter National Health Service Trust (Leicester, United King-
dom). These patients had resections during two periods -
one dating from 1991 to 1994 and the second from Janu-
ary to December 1999. This cohort of patients has been
described previously [26]. Of note, due to exhaustion of
tumour tissue, 133 patient samples with >60 day survival
post surgery were available for analysis in this study. Of
the 133 patients studied, 88 were men and average age at
surgery was 65.8 years (standard deviation, 9.8; range, 33
to 82 years). Full clinicopathologic information was gath-
ered before and after surgery, including patient character-
istics, treatment, combined clinical and surgical staging
results (preoperative staging by computed tomography
scan, selective mediastinoscopy, and systematic lymph
node sampling at operation), histologic subtype, tumour
grade, and survival data. Patients were divided into two
groups: above median survival (AMS) (mean ± SEM 84.0
± 5.1 months) and below median survival (BMS) (mean ±
SEM 10.8 ± 0.8 months). Macrophage-associated TNFα
expression has been described previously in 26 of these
patients [25]. Patient characteristics are shown in Table 1.
Table 1: Patient Characteristics.
Characteristic Extended 
Survival
Poor Survival
No. of patients 67 66
Age - years 66.3 ± 1.2 65.3 ± 1.2
Male sex - no. (%) 39 (58) 49 (74)
Year of surgery - no. (%)
1991 0 (0) 5 (7)
1992 5 (7) 6 (9)
1993 6 (9) 4 (6)
1994 6 (9) 7 (11)
1999 50 (75) 44 (67)
Tumour stage - no. (%)
1 40 (60) 20 (30)
2 18 (27) 19 (29)
3a 9 (13) 23 (35)
3b and 4 0 (0) 4 (6)
Histology - no. (%)
Squamous 39 (58) 29 (44)
Adenocarcinoma 19 (28) 23 (35)
Large cell 4 (6) 8 (12)
Other 5 (7) 6 (9)
Tumour Grade - no. (%)
Well 5 (7) 2 (3)
Moderate 31 (46) 17 (26)
Poor 30 (45) 46 (70)
Not recorded 1 (1) 1 (1)
Adjuvant Chemotherapy (%) 0 (0) 2 (3)
Radiotherapy (%) 8 (12) 12 (18)
Palliative Radiotherapy (%) 7 (10) 9 (14)
Survival - months 84.0 ± 5.1 10.8 ± 0.8
Plus-minus values are means ± SEMOhri et al. BMC Cancer 2010, 10:323
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Immunohistology
Specimens studied were formalin fixed and paraffin
embedded. Only blocks containing the advancing edge of
the primary tumour were evaluated. Tissue sections of 4
μm thickness were cut onto glass slides and then de-
waxed in xylene and rehydrated through graded alcohols.
Antigen retrieval was carried out using Trilogy Antigen
Retrieval solution (Cell Marque, Hot Springs, United
States of America) in a pressure cooker (heated to
117.5°C for 1 min and then cooled to 100°C for 30 sec-
onds). TNFα mouse antihuman antibody was used (clone
P/T2; Abcam, Cambridge, United Kingdom). Immunos-
taining was performed and TNFα was developed with
peroxidase and 3,3'-diaminobenzidine tetrahydrochloride
(brown reaction product). Sections were then counter-
stained with haematoxylin and mounted in an aqueous
mounting medium (BDH Chemicals Ltd, Poole, United
Kingdom). Appropriate isotype controls were performed
where the primary antibodies were replaced by irrelevant
mouse mAb of the same isotype and at the same concen-
tration as the specific primary mAb. To assess whether
TNFα + cells were localised to mast cells, a double-stain
technique described previously by us was used [25,26],
with the mouse monoclonal antibody to human tryptase
(clone AA1, Dako Cytomation, Ely, Cambridgeshire,
United Kingdom) employed to identify mast cells.
Analysis and Validation of Immunostaining
Analysis was performed blind with respect to the clinical
outcome. The ten most representative high-power fields
(x400) per slide were manually selected using an Olym-
pus BX50 microscope (Olympus, Southall, United King-
dom). The respective areas of stroma and tumour islets
were then measured at x400 magnification using Analysis
imaging software (Soft Imaging System GmbH). The
number of nucleated cells with positive staining for TNFα
in each area were then counted manually and expressed
as cells/mm2 o f  s t r o m a  o r  t u m o u r  i s l e t s .  A n a l y s i s  w a s
repeated for 20 patients to assess repeatability and valid-
ity.
Statistical Analysis
Statistical analyses were carried out using the GraphPad
Prism software package (v. 4.02; GraphPad Prism Soft-
ware Inc, San Diego, CA). For categoric analysis, the
median value was used as a cut point to dichotomise the
series. The χ2  test was used to test for relationships
between categoric variables, and the Mann-Whitney
nonparametric test was used to compare categoric with
continuous variables. The Kruskal-Wallis one-way analy-
sis of variance test was used to compare multiple groups.
Kaplan-Meier survival curves were used to look for cor-
relations with survival and were compared with the use of
the log-rank statistic. For the above comparisons, p < 0.05
was considered statistically significant. A multivariate
Cox proportional hazards model was used to estimate
adjusted hazard ratios, 95% CIs, and to identify which of
the macrophage markers were independent prognostic
factors using the Statistical Package for the Social Sci-
ences (SPSS, v. 13.0; SPSS Inc, Chicago, IL). The validity
of the proportional hazards assumption was assessed
from log(-log [Survival]) curves.
Results
Patient Characteristics
Patent characteristics are shown in Table 1. Of the 133
patients studied, 110 had died at the time of analysis.
Thirty-day mortality for the cohort was 4% and patients
who died within the first 60 days of surgery were not
included in this analysis. Sixty-eight tumours were
squamous, 42 adenocarcinoma, 12 large cell, and 11
other. Sixty were stage I, 37 stage II, 32 stage IIIa, and four
stage IIIb or IV. Two patients had additional postopera-
tive chemotherapy and 20 had additional radiotherapy, 16
of whom had it for later palliation. Neither had any effect
on survival. The overall 5-year survival was 31.3%.
Validation of Analysis
Clear and distinguishable staining was evident for TNFα
(Figure 1). Appropriate isotype controls were negative. In
order to assess the validity of the method, area measure-
ments and cell counts were repeated and intraclass corre-
lation coefficients calculated. Good correlations were
found for both: 0.997 (95% CI, 0.996 to 0.998, p < 0.001)
and 0.994 (95% CI, 0.992 to 0.996, p < 0.001). This
method of analysis has also been validated by our group
previously [26].
Cellular Distribution
There was increased expression of TNFα in the tumour
islets of patients with AMS compared to those with BMS
(median 27.2 versus 18.8 cells/mm2  respectively, p =
0.006). There was no significant difference in the expres-
sion of stromal TNFα between the two groups (AMS 23.8
versus BMS 16.8 cells/mm2, p = 0.31) (Figures 2A and
2B).
Figure 1 Immunohistology demonstrating positive TNFα expres-
sion (brown). Magnification ×100.
Ohri et al. BMC Cancer 2010, 10:323
http://www.biomedcentral.com/1471-2407/10/323
Page 4 of 9
Clinical Outcome
Scatter plots of the raw data of TNFα density versus sur-
vival are shown in Figure 3. Spearman's rank correlation
coefficient was calculated to assess any potential relation-
ship with survival. A direct relationship between tumour
islet TNFα density and survival was noted (rs = 0.213, p =
0.01). No significant relationship was seen between sur-
vival and stromal TNFα density (rs = -0.01, p = 0.90).
Kaplan-Meier Survival Analysis
For further analysis, the data were divided into two or
three equal groups according to TNFα density. Kaplan-
Meier survival curves were plotted and the log-rank sta-
tistic used to compare survival rates. When looking at
two groups separated by the median, there was a non-sig-
nificant trend for improved survival with above median
TNFα expression in the tumour islets (p = 0.15, not
shown). When divided into tertiles, there was signifi-
cantly improved survival in the top tertile of TNFα
expression in the tumour islets compared to the middle
and lower tertiles (Figure 4A). Thus patients with high
islet TNFα expression (upper tertile) were noted to have a
significantly higher 5-year predicted survival as opposed
to patients with low TNFα expression (lower tertile) (43%
versus 22%, p = 0.01). There was no significant relation-
ship between TNFα expression in the stroma and survival
(Figure 4B). Similar differences in survival with respect to
TNFα expression in the tumour islets were also evident
within tumour stages (Figure 5), although the differences
did not reach statistical significance due to the smaller
numbers within each stage. Interestingly, patients with
stage IIIa disease in the top tertile of islet TNFα expres-
sion had a 5 year survival of 25% compared to 26% sur-
vival for those patients with stage I disease in the lower
tertile of islet TNFα expression.
Multivariate Cox Proportional Hazards Analysis
A Multivariate Cox Proportional Hazards model was
used to estimate adjusted hazard ratios, 95% CIs, and to
assess whether TNFα islet or stromal counts were inde-
pendent prognostic factors, using a forward stepwise
Figure 2 TNFα densities in Above Median Survival (AMS) and Below Median Survival (BMS) patients in the tumour islets (A) and stroma (B).
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Figure 3 Raw data of cell counts expressing TNFα plotted against 
survival in days in the tumour islets (A) and stroma (B).
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method with a probability of 0.05 for entry and 0.10 for
removal by likelihood ratio statistics. Results of the multi-
variate analysis are shown in Table 2. Continuous vari-
ables were used for islet and stromal TNFα. For every
increase of 1 in the value of the variable, the hazard
increases by the value of the hazard ratio. Expression of
TNFα in the tumour islets emerged as a significant inde-
pendent predictor of survival (hazard ratio 0.995, 95% CI
0.989 to 1.000, p = 0.048). Surprisingly, expression of
TNFα in the tumour stroma emerged as a significant
independent predictor of reduced survival (hazard ratio
1.007, 95% CI 1.002 to 1.011, p = 0.007). There was no
evidence of violation of the proportional hazards assump-
tion.
Cellular localisation of TNFα
We have shown previously that in patients with extended
survival, there is increased expression of macrophages in
the tumour islets compared to patients with poor survival
[26], and that in a separate study the majority of tumour
islet macrophages expressed TNFα [25]. Macrophages
accounted for approximately 60% of the TNFα + cells in
the extended survival patients. While there was a marked
difference in the number of TNFα + macrophages
between extended survival and poor survival islets [25], it
is evident from Figure 2 that the difference in total TNFα
expression in this cohort of 133 patients is not so marked.
Based on morphology, it was considered that a propor-
tion of the TNFα + cells that were not macrophages may
be mast cells. We therefore analysed the cellular distribu-
tion of TNFα expressed by mast cells (Figure 6) in the
subset of samples previously stained for macrophage-
TNFα (AMS [n = 20] and BMS [n = 20]) [25]. In keeping
with our previous observations [26], mast cell numbers
were significantly increased in the islets of the AMS com-
pared to BMS patients (medians 22.6 versus 0.7 cells/
mm2, p < 0.001). Interestingly, mast cells accounted for
45.2% of TNFα expression in the islets of the AMS
patients, but only 5.2% of the BMS patients (Table 3)(p <
0.001). Thus taking macrophage and mast cell-associated
TNFα together, approximately 100% of islet TNFα was
localized to mast cells or macrophages in the subset of
AMS patients studied, while in the islets of the subset of
BMS patients studied, only 28% of TNFα immunoreactiv-
ity was localized to these cells (Table 3) (p < 0.001). Simi-
lar results were evident in the tumour stroma (Table 3, p
< 0.001). This is interesting because it demonstrates that
in BMS patients, there is robust TNFα expression by cells
other than macrophages and mast cells. These cells were
predominantly mononuclear cells and rarely tumour epi-
thelial cells. This suggests that TNFα is highly beneficial
only when localized to macrophages and mast cells in
tumour islets, and not when expressed by other cell types.
Figure 4 Kaplan-Meier five year survival curve for TNFα densities 
in the tumour islets (A) and stroma (B) divided into high counts 
(upper tertile), midrange counts (middle tertile) and low counts 
(lower tertile). The p values in (A) and (B) reflect the difference be-
tween the upper tertile and middle tertile groups and also the differ-
ence between the upper and lower tertile groups.
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Table 2: Results of Cox Regression Analysis.
Factor Hazard Ratio 95% CI p
Islet TNFα 0.995* 0.989 to 1.000 0.048†
Stromal TNFα 1.006* 1.002 to 1.011 0.007†
Age 1.022 1.000 to 1.043 0.049†
Pathological stage 0.002†
I1 . 0 0 0
II 0.283‡ 0.077 to 1.035 0.056
IIIa 0.373 0.102 to 1.372 0.138
IIIb and IV 0.712 0.194 to 2.619 0.609
Grade - differentiated 0.078†
Well 1.000
Moderate 0.481§ 0.177 to 1.306 0.151
Poor 0.752 0.488 to 1.159 0.197
Histology 0.711
Squamous 1.000
Adenocarcinoma 0.708 0.323 to 1.553 0.389
Large 0.828 0.363 to 1.891 0.654
Other NSCLC 0.621 0.235 to 1.640 0.336
*Continuous variable used. For every increase of 1 in the value of the variable, the hazard increases by the value of the hazard ratio.
† Overall significance as a prognostic factor
‡ Hazard relative to stage I
§ Hazard relative to well differentiated
¶ Hazard relative to squamous
Table 3: Assessment of the percentage of cell types expressing TNFα in patients with NSCLC in above median survival 
patients in the islets (AMSI) and stroma (AMSS) and below median survival patients in the islets (BMSI) and stroma (BMSS).
AMSI AMSS BMSI BMSS
% of cells which were Macrophages 61.8*
(9.4-100)
76.9†
(16.6-100)
22.2
(5-71.5)
39.7
(0-61.9)
% of cells which were mast cells 45.2#
(20.3-58.4)
54.9¶
(0-79.1)
5.6
(0-100)
10.5
(0-55)
Estimated % of other cell types 0 0 72 50
*p < 0.001 compared to BMSI; †p < 0.001 compared to BMSS; #p < 0.001 compared to BMSI; ¶p < 0.001 compared to BMSS. We analysed the 
cellular distribution of TNFα expressed by mast cells in the subset of samples previously stained for macrophage-TNFα [25].Ohri et al. BMC Cancer 2010, 10:323
http://www.biomedcentral.com/1471-2407/10/323
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Discussion and Conclusions
The purpose of this study was to investigate the relation-
ship between the microanatomical expression of TNFα
and survival in surgically resected NSCLC. The results
demonstrate that expression of TNFα in the tumour islets
is associated with a significant increase in 5-year survival,
independently of other favorable prognostic factors
including stage, and that TNFα expression in the stroma
is an independent predictor of reduced survival.
The role of TNFα in tumour biology remains contro-
versial with both pro-tumourigenic and anti-tumouri-
genic properties identified [8-10,21,27]. Two small
previous studies of patients with NSCLC suggested TNFα
expression had little relationship to clinical outcome, but
these did not distinguish between expression in tumour
stroma and epithelial islets. The biology of these two
tumour compartments demonstrates profound differ-
ences in matrix composition, cellular content and vascu-
larity. Our previous studies [25,26] have demonstrated
the importance of anatomical microlocalisation in terms
of potential sites for cytotoxicity against tumours. The
key findings of these studies was that tumour epithelial
islets are the likely site of host cytotoxic responses against
tumour progression because patients with extended sur-
vival have infiltration of their tumour islets with mast
cells and macrophages [25,26]. Many cytokine-dependent
effects are mediated through localized cell-cell contact,
including the presentation of membrane-bound TNFα to
TNFα-receptor + cells [28]. The effects of cytokines
including TNFα on tumour stroma versus islets are there-
fore likely to vary profoundly depending on the site of
release, and the cell-cell interactions between TNFα-pro-
ducing cells and the cells they interact with. We therefore
analysed TNFα expression with close attention to expres-
sion in the stroma versus the tumour islets.
In keeping with biological relevance of this concept,
patients with AMS survival had greater immunoreactive
TNFα expression in their tumour islets compared to
those with BMS, and there was a positive correlation
between increasing islet TNFα + cell density and survival.
In addition, when our patient cohort was divided into ter-
tiles according to islet TNFα + cell density we observed
that patients with high expression (upper tertile) had sig-
nificantly improved 5-year survival. Thus increasing
expression of TNFα in the tumour islets was associated
with a significant increase in 5-year survival, indepen-
dently of other favorable prognostic factors. Conversely,
although the density of TNFα + cells in the stroma was
similar in AMS and BMS patients, TNFα expression in
the stroma emerged as an independent predictor of
reduced survival following Cox regression analysis. These
results indicate that the micro-anatomical location of
TNFα expression is potentially critical in determining its
role in tumour biology.
Tumour stage is a key determinant of survival following
surgery for NSCLC [1]. We were able to show that the
relationship between survival and islet TNFα expression
was evident within tumour stages although due to the rel-
atively small numbers for each stage the differences did
not reach statistical significance. Patients with stage I dis-
ease survive longer than patients with stage IIIa disease
[1]. However , when tumour islet TNFα expression was
compared by stage with respect to survival, it was of note
t h a t  p a t i e n t s  w i t h  s t a g e  I I I a  N S C L C  a n d  h i g h  T N F α
expression had a 5-year survival of 25%, comparable to
that of stage I NSCLC patients with low TNFα expres-
sion, who had a 5-year survival of 26%. Conversely,
patients with stage I NSCLC and high TNFα expression
have a 5-year survival of 46%. This suggests that TNFα
expression within tumour islets is therefore a key deter-
minant of NSCLC survival within stage, even within early
stage disease.
A striking observation from this study was the cellular
distribution of TNFα immunoreactivity in the tumour
islets of patients with extended survival compared to
those with poor survival. The macrophages which infil-
trate the tumour islets in NSCLC are predominantly of
the M1 cytotoxic phenotype [25] which express TNFα.
W e  h a v e  e x t e n d ed  t h i s  w o r k  i n  t h e  c u r r e n t  s t u d y  a n d
show that mast cells within the tumour islets also express
TNFα. What is striking, however, is that in the subset of
patients with extended survival, all TNFα islet immuno-
reactivity was accounted for by macrophages and mast
cells. In the subset of patients with poor survival, TNFα
expression in the islets was also evident, but was rarely
present in mast cells or macrophages. Thus it is not only
Figure 6 Mast cell immunohistochemical double-staining 
tryptase (brown) and TNFα (red) demonstrating the presence of 
TNFα in tryptase + mast cells. Arrowhead = double-stain cell. Black 
arrow = single-stain red cell. Grey arrow = single-stain brown cell.
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expression of TNFα in the tumour islets that is critical in
determining survival, but perhaps more importantly, the
type of cells which are expressing it.
The distinction of tumour islets versus stroma is
important as there is evidence suggesting that TNFα
located in the stroma contributes towards tumour prolif-
eration via angiogenesis [29]. In support of this, although
there was no difference in the stromal density of TNFα +
cells in AMS versus BMS patients, increasing stromal
TNFα expression emerged as an independent predictor
of worse survival. Whether this is due to the effects of
TNFα on the stroma or a reflection of the inability of
potentially beneficial TNFα-expressing macrophages and
mast cells to infiltrate the islets is not known. The latter
could be explained by an inappropriate chemokine reper-
toire released by the tumour stroma or even by a physical
barrier, such as a thickened basement membrane,
between the stroma and tumour islets.
The results of this study add to our previous work and
have important clinical implications. We have shown that
the density of TNFα + cells in tumour islets is a predictor
of extended survival in NSCLC following surgery. Its
localization to macrophages and mast cells in the tumour
islets is the key factor relating to improved prognosis, and
it seems unlikely that anti-TNFα strategies will be benefi-
cial to such patients. In contrast, in poor prognosis
patients whose tumours contain relatively few TNFα +
macrophages and/or mast cells, anti-TNFα strategies may
be worthy of further study as stromal expression is an
independent predictor of poor survival. In view of the
marked microanatomical and immunological heteroge-
neity within the tumour microenvironment in NSCLC, it
is essential that attention is paid to this principle in future
immunomodulatory trials in this disease. Targeting sub-
phenotypes of disease with immunopathology predicted
to respond to the intervention may then lead to the devel-
opment of better anti-neoplastic therapeutic strategies.
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